Product Description
A monoclonal antibody directed against reticulon-4, with immunomodulating activity. Atinumab binds to reticulon-4, stimulating neurite outgrowth, which may prevent neuronal damage or may facilitate the regeneration of damaged neurons. (Sourced from: https://www.semanticscholar.org/topic/Atinumab/10982766)
Mechanisms of Action: NOGO Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Spinal Cord Injuries
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00406016 |
CATI355A2102 | P1 |
Completed |
Spinal Cord Injuries |
2011-09-01 |
2019-03-21 |
Treatments |
|
2016-001227-31 |
2016-001227-31 | P2 |
Completed |
Spinal Cord Injuries |
2023-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|